| Year |
Citation |
Score |
| 2011 |
Machu TK. Therapeutics of 5-HT3 receptor antagonists: current uses and future directions. Pharmacology & Therapeutics. 130: 338-47. PMID 21356241 DOI: 10.1016/j.pharmthera.2011.02.003 |
0.379 |
|
| 2009 |
de Oliveira-Pierce AN, Zhang R, Machu TK. Colchicine: a novel positive allosteric modulator of the human 5-hydroxytryptamine3A receptor. The Journal of Pharmacology and Experimental Therapeutics. 329: 838-47. PMID 19188483 DOI: 10.1124/jpet.108.146522 |
0.442 |
|
| 2007 |
Zhang R, Wen X, Militante J, Hester B, Rhubottom HE, Sun H, Leidenheimer NJ, Yan D, White MM, Machu TK. The role of loop F residues in determining differential d-tubocurarine potencies in mouse and human 5-hydroxytryptamine 3A receptors. Biochemistry. 46: 1194-204. PMID 17260949 DOI: 10.1021/Bi0616100 |
0.527 |
|
| 2006 |
Zhang R, White NA, Soti FS, Kem WR, Machu TK. N-terminal domains in mouse and human 5-hydroxytryptamine3A receptors confer partial agonist and antagonist properties to benzylidene analogs of anabaseine. The Journal of Pharmacology and Experimental Therapeutics. 317: 1276-84. PMID 16551836 DOI: 10.1124/Jpet.106.101485 |
0.428 |
|
| 2006 |
Hu XQ, Hayrapetyan V, Gadhiya JJ, Rhubottom HE, Lovinger DM, Machu TK. Mutations of L293 in transmembrane two of the mouse 5-hydroxytryptamine3A receptor alter gating and alcohol modulatory actions. British Journal of Pharmacology. 148: 88-101. PMID 16520747 DOI: 10.1038/sj.bjp.0706685 |
0.385 |
|
| 2006 |
Davies DL, Asatryan L, Kuo ST, Woodward JJ, King BF, Alkana RL, Xiao C, Ye JH, Sun H, Zhang L, Hu XQ, Hayrapetyan V, Lovinger DM, Machu TK. Effects of ethanol on adenosine 5'-triphosphate-gated purinergic and 5-hydroxytryptamine receptors. Alcoholism, Clinical and Experimental Research. 30: 349-58. PMID 16441284 DOI: 10.1111/J.1530-0277.2006.00023.X |
0.368 |
|
| 2003 |
Sessoms-Sikes JS, Hamilton ME, Liu LX, Lovinger DM, Machu TK. A mutation in transmembrane domain II of the 5-hydroxytryptamine(3A) receptor stabilizes channel opening and alters alcohol modulatory actions. The Journal of Pharmacology and Experimental Therapeutics. 306: 595-604. PMID 12730353 DOI: 10.1124/jpet.103.050542 |
0.352 |
|
| 2003 |
Das P, Bell-Horner CL, Machu TK, Dillon GH. The GABA(A) receptor antagonist picrotoxin inhibits 5-hydroxytryptamine type 3A receptors. Neuropharmacology. 44: 431-8. PMID 12646280 DOI: 10.1016/S0028-3908(03)00032-7 |
0.386 |
|
| 2002 |
Coultrap SJ, Machu TK. Enhancement of 5-hydroxytryptamine3A receptor function by phorbol 12-myristate, 13-acetate is mediated by protein kinase C and tyrosine kinase activity. Receptors & Channels. 8: 63-70. PMID 12448787 |
0.407 |
|
| 2002 |
Davies DL, Machu TK, Guo Y, Alkana RL. Ethanol sensitivity in ATP-gated P2X receptors is subunit dependent. Alcoholism, Clinical and Experimental Research. 26: 773-8. PMID 12068244 DOI: 10.1111/J.1530-0277.2002.Tb02604.X |
0.342 |
|
| 2000 |
Sun H, Machu TK. Bicuculline antagonizes 5-HT(3A) and alpha2 glycine receptors expressed in Xenopus oocytes. European Journal of Pharmacology. 391: 243-9. PMID 10729364 DOI: 10.1016/S0014-2999(00)00083-2 |
0.382 |
|
| 1998 |
Machu TK. Colchicine competitively antagonizes glycine receptors expressed in Xenopus oocytes. Neuropharmacology. 37: 391-6. PMID 9681937 DOI: 10.1016/S0028-3908(98)00021-5 |
0.373 |
|
| 1995 |
Harris RA, Mihic SJ, Dildy-Mayfield JE, Machu TK. Actions of anesthetics on ligand-gated ion channels: role of receptor subunit composition. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 9: 1454-62. PMID 7589987 DOI: 10.1096/fasebj.9.14.7589987 |
0.337 |
|
| 1991 |
Leidenheimer NJ, Machu TK, Endo S, Olsen RW, Harris RA, Browning MD. Cyclic AMP-dependent protein kinase decreases gamma-aminobutyric acidA receptor-mediated 36Cl- uptake by brain microsacs. Journal of Neurochemistry. 57: 722-5. PMID 1649259 DOI: 10.1111/j.1471-4159.1991.tb03806.x |
0.303 |
|
| Show low-probability matches. |